Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about how well the drug valrubicin (VALSTAR®)
works to help treat the patient's cancer when administered through a nephrostomy tube
inserted through their back into their kidney. The study is also being done to determine how
safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in
which the drug is eliminated from the human body (Pharmacokinetics or PK).
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute